{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:48:55Z","timestamp":1794242935293,"version":"4.9.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.amjcard.2019.10.029","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:02:13Z","timestamp":1573758133000},"page":"S45-S52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"S1","title":["Safety of Sodium-Glucose Co-Transporter 2 Inhibitors"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-6521","authenticated-orcid":false,"given":"Janet B.","family":"McGill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitha","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.10.029_bb0005","unstructured":"Janssen Pharmaceuticals, Inc. Prescribing information: INVOKANA\u00ae(canagliflozin) tablets, for oral use. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204042s027lbl.pdf. Accessed January 25, 2019."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0010","unstructured":"AstraZeneca Pharmaceuticals LP. Prescribing information: FARXIGA\u00ae (dapagliflozin) tablets, for oral use. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202293s017lbl.pdf. Accessed January 25, 2019."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0015","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Prescribing information: JARDIANCE\u00ae (empagliflozin) tablets, for oral use. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204629s018lbl.pdf. Accessed January 25, 2019."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0020","unstructured":"Merck Sharpe & Dohme Corp. Prescribing information: STEGLATRO\u2122 (ertugliflozin) tablets, for oral use. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209803s001lbl.pdf. Accessed January 25, 2019."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes\u2014a systematic review","volume":"140","author":"R\u00e5dholm","year":"2018","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0030","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.diabres.2018.03.047","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: a systematic review and meta-analysis","volume":"140","author":"Zhang","year":"2018","journal-title":"Diabetes Res Clin Pract."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/dom.13047","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Wang","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1507\/endocrj.EJ17-0372","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis","volume":"65","author":"Li","year":"2018","journal-title":"Endocr J."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 inhibitors: are they safe?","volume":"130","author":"Filippas-Ntekouan","year":"2018","journal-title":"Postgrad Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0055","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/00325481.2017.1259544","article-title":"Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"129","author":"Devi","year":"2017","journal-title":"Postgrad Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03007995.2016.1271780","article-title":"Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis","volume":"33","author":"Qiu","year":"2017","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0080","article-title":"Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0085","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0090","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0095","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0100","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0110","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.9778\/cmajo.20180111","article-title":"Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials","volume":"6","author":"Donnan","year":"2018","journal-title":"CMAJ Open."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0115","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0120","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives [epub]","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0130","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0140","article-title":"Diabetes pharmacotherapy and effects on the musculoskeletal system","volume":"35","author":"Kalaitzoglou","year":"2018","journal-title":"Diabetes Metab Res Rev."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/00325481.2017.1256747","article-title":"Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus","volume":"129","author":"Blevins","year":"2017","journal-title":"Postgrad Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0155","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/M18-0567","article-title":"Fracture risk after initiation of use of canagliflozin: a cohort study","volume":"170","author":"Fralick","year":"2019","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0165","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3389\/fphar.2018.01517","article-title":"Qu X. Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk","volume":"9","author":"Ye","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0170","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1530\/EC-18-0456","article-title":"Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties","volume":"8","author":"Picke","year":"2019","journal-title":"Endocr Connect."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0175","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0180","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1007\/s00125-017-4430-0","article-title":"Bladder cancer in the EMPA-REG OUTCOME trial","volume":"60","author":"Kohler","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0185","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00125-018-4664-5","article-title":"Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events","volume":"61","author":"Ohkuma","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1470-2045(14)71123-4","article-title":"Global burden of cancer attributable to high body-mass index in 2012: a population-based study","volume":"16","author":"Arnold","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0195","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2019.10.029_bb0200","unstructured":"US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM475487.pdf. Accessed February 11, 2019."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0205","unstructured":"US Food and Drug Administration. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM506772.pdf. Accessed February 11, 2019."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0210","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0215","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/dom.12876","article-title":"Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus","volume":"19","author":"Desai","year":"2017","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0220","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0225","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0230","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.diabet.2018.02.001","article-title":"Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"44","author":"Li","year":"2018","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0235","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0240","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study","volume":"20","author":"Yuan","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0245","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0250","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study","volume":"20","author":"Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0255","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0260","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA adverse event reporting system","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0265","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/dom.13255","article-title":"SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect?","volume":"20","author":"Khouri","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0270","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41574-018-0001-9","article-title":"Does lower limb amputation concern all SGLT2 inhibitors?","volume":"14","author":"Scheen","year":"2018","journal-title":"Nat Rev Endocrinol."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12902-019-0353-8","article-title":"Incidence and determinants of diabetes-related lower limb amputations in Ghana, 2010-2015\u2014a retrospective cohort study","volume":"19","author":"Sarfo-Kantanka","year":"2019","journal-title":"BMC Endocr Disord."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0280","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","article-title":"Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use","volume":"62","author":"Potier","year":"2019","journal-title":"Diabetologia."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jamcollsurg.2016.10.025","article-title":"Finding the evidence in real-world evidence: moving from data to information to knowledge","volume":"224","author":"Schilsky","year":"2017","journal-title":"J Am Coll Surg."},{"key":"10.1016\/j.amjcard.2019.10.029_bb0290","doi-asserted-by":"crossref","unstructured":"Patorno E, Pawar A, Franklin JM, et al. Comparative effectiveness and safety of empagliflozin: an interim analysis from the empagliflozin comparative effectiveness and safety (EMPRISE) study. J Am Coll Cardiol. 2019;73(Suppl 1). Available at: http:\/\/www.onlinejacc.org\/content\/73\/9_Supplement_1\/683.","DOI":"10.1016\/S0735-1097(19)31291-4"},{"key":"10.1016\/j.amjcard.2019.10.029_bb0295","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","article-title":"SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL","volume":"71","author":"Cavender","year":"2018","journal-title":"J Am Coll Cardiol."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919311798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:05:24Z","timestamp":1762077924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919311798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":59,"alternative-id":["S0002914919311798"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.029","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Sodium-Glucose Co-Transporter 2 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}